Same sparkle, different story: how lab-grown diamonds are transforming the market 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
World game at war: why some European nations have threatened a World Cup boycott 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
VANCOUVER, British Columbia and WARMINSTER, Pa., April 30, 2018 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 3, 2018 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss first quarter 2018 financial results and provide a corporate update.
To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 4169558.
About Arbutus
Arbutus Biopharma Corporation is a publicly traded (Nasdaq:ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care (SOC) and contribute to a curative combination regimen to improve patient outcomes and deliver a potential cure for HBV. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Tiffany Tolmie
Manager, Investor Relations
Phone: 604-419-3200
Email: [email protected]
Media
David Schull
Russo Partners
Phone: 858-717-2310
Email: [email protected]
